What is Globus Med Inc's earnings per share (EPS)?

Globus Med Inc (GMED) reported diluted earnings per share of $3.92 for fiscal year 2025. This represents a 422.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Globus Med Inc Financials

GMED

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Globus Med Inc (GMED) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 69/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Globus Med Inc has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is up from 6.6% the prior year.

Growth

Globus Med Inc's revenue surged 16.7% year-over-year to $2.9B, reflecting rapid business expansion. This strong growth earns a score of 61/100.

Leverage

Globus Med Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.26, Globus Med Inc holds $4.26 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 84/100.

Cash Flow

Globus Med Inc converts 20.0% of revenue into free cash flow ($588.8M). This strong cash generation earns a score of 75/100.

Returns

Globus Med Inc's ROE of 11.8% shows moderate profitability relative to equity, earning a score of 37/100. This is up from 2.5% the prior year.

Altman Z-Score Safe

11.37

Globus Med Inc scores 11.37, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.9B) relative to total liabilities ($729.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

Globus Med Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.40x

For every $1 of reported earnings, Globus Med Inc generates $1.40 in operating cash flow ($753.4M OCF vs $537.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.9B

YoY+16.7%

5Y CAGR+30.1%

10Y CAGR+18.4%

Globus Med Inc generated $2.9B in revenue in fiscal year 2025. This represents an increase of 16.7% from the prior year.

EBITDA

$756.7M

YoY+80.4%

5Y CAGR+34.1%

10Y CAGR+14.4%

Globus Med Inc's EBITDA was $756.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 80.4% from the prior year.

Net Income

$537.9M

YoY+422.3%

5Y CAGR+39.4%

10Y CAGR+16.9%

Globus Med Inc reported $537.9M in net income in fiscal year 2025. This represents an increase of 422.3% from the prior year.

EPS (Diluted)

$3.92

YoY+422.7%

5Y CAGR+31.2%

10Y CAGR+12.9%

Globus Med Inc earned $3.92 per diluted share (EPS) in fiscal year 2025. This represents an increase of 422.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$588.8M

YoY+45.3%

5Y CAGR+34.2%

10Y CAGR+23.2%

Globus Med Inc generated $588.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.3% from the prior year.

Cash & Debt

$526.2M

YoY-32.9%

5Y CAGR+17.1%

10Y CAGR+24.7%

Globus Med Inc held $526.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

67.4%

YoY+8.5pp

5Y CAGR-5.0pp

10Y CAGR-8.3pp

Globus Med Inc's gross margin was 67.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 8.5 percentage points from the prior year.

Operating Margin

16.3%

YoY+9.7pp

5Y CAGR+2.2pp

10Y CAGR-15.3pp

Globus Med Inc's operating margin was 16.3% in fiscal year 2025, reflecting core business profitability. This is up 9.7 percentage points from the prior year.

Net Margin

18.3%

YoY+14.2pp

5Y CAGR+5.3pp

10Y CAGR-2.4pp

Globus Med Inc's net profit margin was 18.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 14.2 percentage points from the prior year.

Return on Equity

11.8%

YoY+9.3pp

5Y CAGR+5.0pp

10Y CAGR-4.0pp

Globus Med Inc's ROE was 11.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 9.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$147.2M

YoY-10.1%

5Y CAGR+11.7%

10Y CAGR+15.0%

Globus Med Inc invested $147.2M in research and development in fiscal year 2025. This represents a decrease of 10.1% from the prior year.

Share Buybacks

$300.5M

YoY+250.2%

5Y CAGR+23.5%

Globus Med Inc spent $300.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 250.2% from the prior year.

Capital Expenditures

$164.7M

YoY+42.7%

5Y CAGR+20.9%

10Y CAGR+12.5%

Globus Med Inc invested $164.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 42.7% from the prior year.

GMED Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.9B+16.7%	$2.5B+60.6%	$1.6B+53.3%	$1.0B+6.8%	$958.1M+21.4%	$789.0M
Cost of Revenue	$957.8M-7.5%	$1.0B+88.9%	$548.2M+107.9%	$263.7M+10.2%	$239.2M+10.0%	$217.5M
Gross Profit	$2.0B+33.5%	$1.5B+45.4%	$1.0B+34.4%	$759.1M+5.6%	$718.9M+25.8%	$571.6M
R&D Expenses	$147.2M-10.1%	$163.8M+32.0%	$124.0M+69.8%	$73.0M-25.0%	$97.3M+15.2%	$84.5M
SG&A Expenses	$1.2B+20.1%	$981.4M+52.4%	$643.8M+49.0%	$432.1M+5.9%	$408.1M+15.1%	$354.8M
Operating Income	$479.8M+189.1%	$166.0M+24.7%	$133.1M-41.6%	$228.0M+32.6%	$172.0M+54.3%	$111.4M
Interest Expense	N/A	-$4.2M-120.8%	$20.1M+41.4%	$14.2M+53.1%	$9.3M-33.4%	$14.0M
Income Tax	$67.2M+278.8%	$17.7M-58.3%	$42.5M-19.5%	$52.9M+69.3%	$31.2M+32.2%	$23.6M
Net Income	$537.9M+422.3%	$103.0M-16.2%	$122.9M-35.4%	$190.2M+27.5%	$149.2M+45.9%	$102.3M
EPS (Diluted)	$3.92+422.7%	$0.75-29.9%	$1.07-42.2%	$1.85+28.5%	$1.44+42.6%	$1.01

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$826.4M+7.5%	$769.0M+3.2%	$745.3M+24.6%	$598.1M-9.0%	$657.3M+5.0%	$625.7M-0.6%	$629.7M+3.8%	$606.7M
Cost of Revenue	$261.1M+3.4%	$252.5M+1.5%	$248.8M+27.3%	$195.4M-25.8%	$263.4M-2.6%	$270.5M+4.0%	$260.0M+7.7%	$241.5M
Gross Profit	$565.3M+9.4%	$516.5M+4.0%	$496.6M+23.3%	$402.7M+2.3%	$393.9M+10.9%	$355.2M-3.9%	$369.7M+1.2%	$365.2M
R&D Expenses	$36.2M-5.0%	$38.1M-4.7%	$40.0M+20.8%	$33.1M-1.0%	$33.4M-5.6%	$35.4M-6.1%	$37.7M-34.2%	$57.3M
SG&A Expenses	$318.5M+1.6%	$313.6M+3.3%	$303.6M+25.1%	$242.8M-4.1%	$253.2M+5.5%	$240.1M+0.3%	$239.5M-3.7%	$248.7M
Operating Income	$169.3M+23.3%	$137.4M+80.5%	$76.1M-21.5%	$97.0M+60.9%	$60.3M+25.3%	$48.1M-3.1%	$49.6M+520.5%	$8.0M
Interest Expense	N/A	$1.5M+110.0%	$693K-58.8%	$1.7M+106.3%	$815K+205.2%	-$775K+66.8%	-$2.3M-23.3%	-$1.9M
Income Tax	$28.6M+14.4%	$25.0M+270.6%	-$14.7M-152.0%	$28.2M+1634.6%	-$1.8M-135.4%	$5.2M-67.2%	$15.8M+1197.9%	-$1.4M
Net Income	$140.6M+18.2%	$119.0M-41.4%	$202.8M+168.8%	$75.5M+184.7%	$26.5M-48.9%	$51.8M+63.2%	$31.8M+546.3%	-$7.1M
EPS (Diluted)	N/A	$0.88-40.9%	$1.49+175.9%	$0.54	N/A	$0.38+65.2%	$0.23+560.0%	$-0.05

GMED Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.3B+1.0%	$5.3B+3.3%	$5.1B+145.0%	$2.1B+6.1%	$2.0B+16.5%	$1.7B
Current Assets	$2.1B-2.4%	$2.2B+13.7%	$1.9B+94.8%	$983.3M+13.7%	$864.5M+5.2%	$821.8M
Cash & Equivalents	$526.2M-32.9%	$784.4M+67.9%	$467.3M+210.6%	$150.5M-22.1%	$193.1M-19.4%	$239.4M
Inventory	$759.3M+15.2%	$659.2M-22.3%	$848.1M+183.7%	$299.0M+26.2%	$237.0M+3.4%	$229.2M
Accounts Receivable	$678.9M+21.7%	$557.7M+10.8%	$503.2M+136.0%	$213.2M+29.7%	$164.4M+16.1%	$141.7M
Goodwill	$1.4B+0.2%	$1.4B-0.2%	$1.4B+626.5%	$197.5M+9.9%	$179.7M+14.7%	$156.7M
Total Liabilities	$729.5M-32.1%	$1.1B-1.3%	$1.1B+373.6%	$229.8M+6.4%	$215.9M+24.6%	$173.2M
Current Liabilities	$498.5M-41.8%	$855.9M+118.2%	$392.3M+146.4%	$159.2M+13.6%	$140.2M+16.0%	$120.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.6B+9.5%	$4.2B+4.5%	$4.0B+116.5%	$1.8B+6.0%	$1.7B+15.6%	$1.5B
Retained Earnings	$1.4B+20.4%	$1.2B+1.4%	$1.1B-8.3%	$1.2B+3.8%	$1.2B+14.3%	$1.0B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$5.3B+4.1%	$5.1B+2.7%	$5.0B+5.3%	$4.7B-10.3%	$5.3B+3.3%	$5.1B+1.8%	$5.0B+1.0%	$4.9B
Current Assets	$2.1B+10.5%	$1.9B+11.2%	$1.7B+1.2%	$1.7B-21.5%	$2.2B+5.9%	$2.1B+6.9%	$1.9B+5.2%	$1.8B
Cash & Equivalents	$526.2M+41.5%	$371.8M+62.0%	$229.4M-50.3%	$461.3M-41.2%	$784.4M+26.0%	$622.8M+51.7%	$410.4M+15.9%	$354.1M
Inventory	$759.3M-1.6%	$771.5M-0.1%	$772.1M+16.4%	$663.6M+0.7%	$659.2M-8.1%	$717.7M-6.8%	$770.5M-5.6%	$816.2M
Accounts Receivable	$678.9M+9.7%	$619.1M+1.2%	$611.6M+14.3%	$535.1M-4.1%	$557.7M-5.2%	$588.0M-3.9%	$611.8M+14.5%	$534.3M
Goodwill	$1.4B+0.1%	$1.4B0.0%	$1.4B+0.1%	$1.4B0.0%	$1.4B+0.1%	$1.4B-1.5%	$1.5B+0.2%	$1.5B
Total Liabilities	$729.5M+4.7%	$696.8M+4.7%	$665.4M+6.8%	$623.1M-42.0%	$1.1B+5.7%	$1.0B-0.1%	$1.0B-0.4%	$1.0B
Current Liabilities	$498.5M+7.0%	$466.0M+9.7%	$424.7M+10.4%	$384.7M-55.1%	$855.9M+4.6%	$818.1M+3.0%	$794.1M+1.0%	$786.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.6B+4.0%	$4.4B+2.4%	$4.3B+5.1%	$4.1B-2.1%	$4.2B+2.7%	$4.1B+2.3%	$4.0B+1.4%	$3.9B
Retained Earnings	$1.4B+7.4%	$1.3B+6.5%	$1.2B+17.1%	$1.0B-10.1%	$1.2B+2.4%	$1.1B+4.8%	$1.1B+2.6%	$1.0B

GMED Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$753.4M+44.7%	$520.6M+113.8%	$243.5M+36.4%	$178.5M-35.4%	$276.3M+39.0%	$198.8M
Capital Expenditures	$164.7M+42.7%	$115.4M+47.5%	$78.3M+5.7%	$74.0M+30.1%	$56.9M-10.6%	$63.7M
Free Cash Flow	$588.8M+45.3%	$405.2M+145.2%	$165.2M+58.2%	$104.4M-52.4%	$219.4M+62.3%	$135.1M
Investing Cash Flow	-$355.0M-101.7%	-$176.1M-158.1%	$303.0M+374.5%	-$110.4M+70.6%	-$375.9M-220.4%	-$117.3M
Financing Cash Flow	-$679.2M-2352.2%	-$27.7M+88.1%	-$231.8M-110.8%	-$110.0M-303.1%	$54.1M+240.0%	-$38.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$300.5M+250.2%	$85.8M-62.0%	$225.6M+56.1%	$144.5M	N/A	$104.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$248.6M-0.4%	$249.7M+220.7%	$77.9M-56.1%	$177.3M-15.7%	$210.3M+3.3%	$203.7M+275.3%	$54.3M+3.6%	$52.4M
Capital Expenditures	$46.2M+29.0%	$35.8M-23.1%	$46.6M+29.0%	$36.1M+111.0%	$17.1M-59.2%	$42.0M+50.9%	$27.8M-2.7%	$28.6M
Free Cash Flow	$202.4M-5.4%	$213.9M+583.3%	$31.3M-77.8%	$141.2M-26.9%	$193.2M+19.5%	$161.7M+511.1%	$26.5M+11.1%	$23.8M
Investing Cash Flow	-$111.4M-46.9%	-$75.8M+74.6%	-$299.1M-327.7%	$131.4M+226.2%	-$104.1M-595.7%	-$15.0M-44.2%	-$10.4M+77.7%	-$46.6M
Financing Cash Flow	$13.2M+141.2%	-$32.0M-28.5%	-$24.9M+96.1%	-$635.4M-1163.7%	$59.7M+205.0%	$19.6M+124.9%	$8.7M+107.5%	-$115.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$45.0M+12.5%	$40.0M+60.0%	$25.0M-86.9%	$190.5M+18945.1%	$1.0M	$0-100.0%	$1.5M-98.2%	$83.3M

GMED Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	67.4%+8.5pp	58.9%-6.2pp	65.0%-9.2pp	74.2%-0.8pp	75.0%+2.6pp	72.4%
Operating Margin	16.3%+9.7pp	6.6%-1.9pp	8.5%-13.8pp	22.3%+4.3pp	17.9%+3.8pp	14.1%
Net Margin	18.3%+14.2pp	4.1%-3.7pp	7.8%-10.8pp	18.6%+3.0pp	15.6%+2.6pp	13.0%
Return on Equity	11.8%+9.3pp	2.5%-0.6pp	3.1%-7.2pp	10.3%+1.7pp	8.6%+1.8pp	6.8%
Return on Assets	10.1%+8.2pp	2.0%-0.5pp	2.4%-6.7pp	9.2%+1.5pp	7.6%+1.5pp	6.1%
Current Ratio	4.26+1.7	2.54-2.3	4.88-1.3	6.180.0	6.17-0.6	6.80
Debt-to-Equity	0.16-0.1	0.26-0.0	0.27+0.1	0.120.0	0.120.0	0.12
FCF Margin	20.0%+4.0pp	16.1%+5.5pp	10.5%+0.3pp	10.2%-12.7pp	22.9%+5.8pp	17.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	68.4%+1.3pp	67.2%+0.5pp	66.6%-0.7pp	67.3%+7.4pp	59.9%+3.1pp	56.8%-1.9pp	58.7%-1.5pp	60.2%
Operating Margin	20.5%+2.6pp	17.9%+7.7pp	10.2%-6.0pp	16.2%+7.1pp	9.2%+1.5pp	7.7%-0.2pp	7.9%+6.6pp	1.3%
Net Margin	17.0%+1.5pp	15.5%-11.8pp	27.2%+14.6pp	12.6%+8.6pp	4.0%-4.3pp	8.3%+3.2pp	5.0%+6.2pp	-1.2%
Return on Equity	3.1%+0.4pp	2.7%-2.0pp	4.7%+2.9pp	1.8%+1.2pp	0.6%-0.6pp	1.3%+0.5pp	0.8%+1.0pp	-0.2%
Return on Assets	2.6%+0.3pp	2.3%-1.8pp	4.1%+2.5pp	1.6%+1.1pp	0.5%-0.5pp	1.0%+0.4pp	0.6%+0.8pp	-0.1%
Current Ratio	4.26+0.1	4.13+0.1	4.07-0.4	4.45+1.9	2.54+0.0	2.51+0.1	2.42+0.1	2.33
Debt-to-Equity	0.160.0	0.160.0	0.150.0	0.15-0.1	0.260.0	0.250.0	0.260.0	0.26
FCF Margin	24.5%-3.3pp	27.8%+23.6pp	4.2%-19.4pp	23.6%-5.8pp	29.4%+3.6pp	25.8%+21.6pp	4.2%+0.3pp	3.9%

Similar Companies

Masimo Corp MASI

$9.3B

Bio Rad Labs Inc BIO

$7.6B

iRhythm Holdings, Inc IRTC

$3.8B

Glaukos Corp GKOS

$6.5B

Bruker Corp BRKR

$5.6B

Frequently Asked Questions

What is Globus Med Inc's annual revenue?

Globus Med Inc (GMED) reported $2.9B in total revenue for fiscal year 2025. This represents a 16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Globus Med Inc's revenue growing?

Globus Med Inc (GMED) revenue grew by 16.7% year-over-year, from $2.5B to $2.9B in fiscal year 2025.

Is Globus Med Inc profitable?

Yes, Globus Med Inc (GMED) reported a net income of $537.9M in fiscal year 2025, with a net profit margin of 18.3%.

What is Globus Med Inc's EBITDA?

Globus Med Inc (GMED) had EBITDA of $756.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Globus Med Inc's gross margin?

Globus Med Inc (GMED) had a gross margin of 67.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Globus Med Inc's operating margin?

Globus Med Inc (GMED) had an operating margin of 16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Globus Med Inc's net profit margin?

Globus Med Inc (GMED) had a net profit margin of 18.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Globus Med Inc's return on equity (ROE)?

Globus Med Inc (GMED) has a return on equity of 11.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Globus Med Inc's free cash flow?

Globus Med Inc (GMED) generated $588.8M in free cash flow during fiscal year 2025. This represents a 45.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Globus Med Inc's operating cash flow?

Globus Med Inc (GMED) generated $753.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Globus Med Inc's total assets?

Globus Med Inc (GMED) had $5.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Globus Med Inc's capital expenditures?

Globus Med Inc (GMED) invested $164.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Globus Med Inc spend on research and development?

Globus Med Inc (GMED) invested $147.2M in research and development during fiscal year 2025.

Does Globus Med Inc buy back shares?

Yes, Globus Med Inc (GMED) spent $300.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Globus Med Inc's current ratio?

Globus Med Inc (GMED) had a current ratio of 4.26 as of fiscal year 2025, which is generally considered healthy.

What is Globus Med Inc's debt-to-equity ratio?

Globus Med Inc (GMED) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Globus Med Inc's return on assets (ROA)?

Globus Med Inc (GMED) had a return on assets of 10.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Globus Med Inc's Altman Z-Score?

Globus Med Inc (GMED) has an Altman Z-Score of 11.37, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Globus Med Inc's Piotroski F-Score?

Globus Med Inc (GMED) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Globus Med Inc's earnings high quality?

Globus Med Inc (GMED) has an earnings quality ratio of 1.40x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Globus Med Inc?

Globus Med Inc (GMED) scores 69 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.